News Portfolio

MxEP led the due diligence process and recommended the investment of PI2 in Mablink Bioscience

Published on
2 months 3 weeks ago

Mablink Bioscience, the next generation ADC company, raises €4M from a syndicate of private investors. 

Jérémie Waicenberg, Senior Business Analyst at MxEP, serves as a member of the Board of Directors of the company.